Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | TRIP13 | Q15645 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26083643 | 1.00 | KMT2A (0.52) | KMT2AMEN1ALDH1A1HPGDTRIP13 | |
| SCHEMBL26110277 | 0.90 | ALDH1A1 (0.52) | KMT2AMEN1ALDH1A1HPGDTRIP13 | |
| SCHEMBL26083644 | 0.89 | ALDH1A1 (0.53) | KMT2AMEN1ALDH1A1HPGDTRIP13 | |
| SCHEMBL26109436 | 0.89 | ALDH1A1 (0.51) | KMT2AMEN1ALDH1A1HPGDTRIP13 | |
| SCHEMBL26108154 | 0.89 | ALDH1A1 (0.51) | KMT2AMEN1ALDH1A1HPGDTRIP13 | |
| SCHEMBL31466742 | 0.89 | ALDH1A1 (0.64) | KMT2AMEN1ALDH1A1HPGDTRIP13 | |
| SCHEMBL26084136 | 0.89 | ALDH1A1 (0.64) | KMT2AMEN1ALDH1A1HPGDTRIP13 | |
| SCHEMBL26083642 | 0.89 | ALDH1A1 (0.51) | KMT2AMEN1ALDH1A1HPGDTRIP13 | |
| SCHEMBL26110309 | 0.89 | ALDH1A1 (0.64) | KMT2AMEN1ALDH1A1HPGDTRIP13 | |
| SCHEMBL26109508 | 0.89 | HPGD (0.59) | KMT2AMEN1ALDH1A1HPGDTRIP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034091-A1 | Small molecule inhibitors of lanosterol synthase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-01-30 | — | — | US | disclosed |
| WO-2023192782-A2 | SMALL MOLECULE INHIBITORS OF LANOSTEROL SYNTHASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034091-A1 | Small molecule inhibitors of lanosterol synthase | LSS, CYP51A1, CYP27A1 | KMT2A 4011/4885MEN1 2088/4885ALDH1A1 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.